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Ivabradine, an If inhibitor, acts primarily on the sinoatrial node and is used to reduce the heart rate with minimal eﬀect on
myocardial contractility, blood pressure, and intracardiac conduction. Heart rate reduction is an important aspect of care in
patientswithchronicstableanginaandheartfailure.Manypatientswithcoronaryarterydiseasehavecoexistingasthmaorchronic
obstructive airway disease, and most of them are unable to tolerate beta blockers. Ivabradine may thus be a useful medicine in
therapeutic heart rate management especially in patients who are intolerant of beta-blockers.
Copyright © 2009 Michael Liang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
A higher heart rate is associated with an increase in
cardiovascular mortality both in general population and
in patients with established cardiovascular disease [1–4].
Previous studies have shown that a rapid heart rate is a risk
factor for developing hypertension and atheroscelerosis [5–
7].Inpatientswithsuspectedandestablishedcoronaryartery
disease, an elevated heart rate is an independent predictor
of survival [8–11]. The morbidity-mortality evaluation of
the If inhibitor ivabradine trial (BEAUTIFUL trial) showed
that a heart rate greater than 70 beats per minute (bpm) is
associated with increased cardiovascular death [11].
L o w e rh e a r tr a t er e d u c e sm y o c a r d i a lo x y g e nc o n s u m p -
tion and increases oxygen supply to heart via prolongation
of diastole [12]. This property is important in patients with
chronic stable angina. The stenotic coronary arteries often
receive oxygen supply from less severely stenotic arteries
via collateral branches. Blood ﬂow in collateral branches is
optimized in prolonged diastolic phase. An increase in heart
rate results in a shortened diastole and therefore reduces
blood supply to the stenotic coronaries via collaterals.
Maintaining a stable lower heart rate in these conditions is
beneﬁcial for symptom control [13].
Persistent elevated heart rate is also commonly seen in
patients with congestive heart failure (CHF). Studies in the
past using drugs either increasing or reducing heart rate
showed survival beneﬁt when treatment group had lower
average heart rate than placebo. By contrast, survival was
poorer when average heart rate of the treated cohort had
increased compared with placebo [14].
In addition to existing beta-blockers and non-
dihydropyridine calcium channel inhibitors, If inhibitors
that blocks the If current in sinoatrial node may have a role
in therapeutic heart rate management and angina control
[12]. This could be particularly useful in patients who are
unable to tolerate beta-blockers or non-dihydropyridine
calcium channel inhibitors. In New Zealand, the prevalence
ofasthmaisnearly20%anditiscommontocomeacrossthis
group of patients who are unable to tolerate beta-blockers
[15]. The concept and application of If inhibitor will be
reviewed in this article.
2. The Concept of If Inhibition
If current, ﬁrst described by Brown et al. in 1979, is
activated in phase 4 of action potential in the sinoatrial
node by accelerating diastolic depolarisation [16]. Phase
4 of the cardiac action potential is the resting membrane
potential and a cell remains in this phase until it is
triggered by external electrical stimulus. The sinoatrial node2 Cardiology Research and Practice
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Figure 1: (a) a diagram demonstrates If current and other ionic
currents in phase 4 of action potential. For simplicity IcaL and IcaT
are shown together as Ica. (b) Inhibition of If phase 4 of action
potential leads to reduction of slope from a to b. This results in
prolonged phase 4 or ﬁring frequency of action potential, thus
slower heart rate.
demonstrates automaticity by spontaneous depolarisation
without external electrical or nervous stimulus. This is
mediated by HCN channels (Hyperpolarization-activated,
Cyclic Nucleotide-gated channels) which allows net inward
mixed Na+/K+ current during diastole, that is, phase 4
action potential [13]. Because of this unusual behaviour it
is named “funny” current and therefore so-called pacemaker
current (I for current, f for funny) [17]. Three other ionic
currents associated with this phase of action potential are
Ik, IcaL, IcaT. Ik is activated by preceding action potential
and results in outward movement of potassium through the
slow delayed rectiﬁer potassium channels. The two inward
calcium currents are IcaL (L type/long-lasting Ca channel)
and IcaT (T type/transient Ca channel). The action potential
reaches its threshold (approx. −40mv) by If current which
in turn controls the successive action potential and heart rate
(see Figures 1(a) and 1(b)).
The hyperpolarization-activated, cyclic nucleotide-gated
(HCN) channels are responsible for If current. There are
four isoforms of HCN channels that is, HCN1–HCN4 which
can be found in heart, brain and retina. The main isoform
found in the heart is HCN4 and it is highly expressed in
sinoatrial node [18]. HCN4 channels are also present in
atrio-ventricularnodeandPurkinjeﬁbres;however,theseare
not active under normal physiological condition. If current
might be involved in the pathological role of congestive heart
failure and ventricular hypertrophy, therefore, it is attractive
to search for potential pharmacological inhibitors which
couldresultin heartratereduction with minimal side eﬀects.
3.Ivabradine—theSelectiveand
SpeciﬁcIf Inhibitor
F e wa g e n t sw e r ed e v e l o p e df o rIf inhibition in the past; the
ﬁrst of which is Alinidine, a clonidine derivative, that was
soon abandoned due to its relative inotropic action [19].
Later, zetabradine, a benzazepinone derivative also went out
ofcontentionduetounacceptableocularsideeﬀectsandQTc
prolongation [20, 21].
Ivabradine, a unique speciﬁc If current inhibitor, was
ﬁrst described by Thollon et al. more than a decade ago
[22]. It exhibit dose-dependent heart rate reduction with
minimal eﬀect on myocardial contractility, blood pressure,
intracardiac conduction and ventricular repolarisation [23].
At the treatment dose, ivabradine has no eﬀect on electro-
cardiographic PR or QT (QTc) interval. When compared
with beta-blocker atenolol, ivabradine depresses myocardial
relaxation to a lesser extent both at rest and exercise [24, 25].
4. AdverseEffects with Ivabradine
Common side eﬀects from Ivabradine resulting in with-
drawal of treatment are; visual symptoms such as blurred
vision, phosphenes and visual disturbance. Clinical trials
suggest dose-dependent reversible visual side eﬀects are
relatively small in treatment dose up to 10mg twice daily
[23, 26, 27].
In the BEAUTIFUL trial, symptomatic bradycardia was
the most common adverse eﬀect leading to discontinuation
of treatment, however, 87% of enrolled patients were receiv-
ing beta-blockers at the same time [23].
Since ivabradine targets sino-atrial node for heart rate
control, its use was discouraged in the presence of atrial
ﬁbrillation, persistent pacemaker rhythms and second/third
degree atrio-ventricular block [11, 22, 26].
5. ClinicalTrialsof Ivabradine
The international BEAUTIFUL trial is, to date, the largest
randomized, double-blinded, placebo-controlled trial of
ivabradine [11, 23]. Patients with coronary artery disease
and left-ventricular ejection less than 40% were included
in this trial. Out of 10917 eligible patients, 5479 patients
received 5mg ivabradine gradually titrated to the target
dose of 7.5mg twice a day in addition to conventional
cardiovascular medication. Patients receiving ivabradine had
6bpm reduction in heart rate from the mean baseline of
71.6bpm at 12 months. However, 87% of patients were
also on a beta-blocker. The trial showed that there is no
diﬀerence in primary composite outcome, cardiovascularCardiology Research and Practice 3
death or admission to hospital for new-onset or worsening
heart failure in the study population. However, the analysis
of prespeciﬁed subgroup of patients with a heart rate of
70bpm or greater shows a lower rate of admission to
hospital for myocardial infarction (HR 0.64, P = .001),
myocardial infarction or unstable angina (HR 0.78, P = .23),
and coronary revascularisation (HR 0.70, P = .16). These
ﬁndings suggest a heart rate of 70 or greater in the presence
of coronary artery disease and moderate systolic failure
is associated with increased cardiovascular death, hospital
admission for heart failure or myocardial infarction and
coronary revascularisation. The study also implies that a
heart rate of 75 or less could be target for therapeutic heart
rate management in this group of patients who have higher
baseline heart rate.
The eﬃcacy of ivabradine as monotherapy in angina
control was tested in a randomized double-blinded trial by
Borer et al. [28] 360 patients with chronic stable angina were
assigned to either placebo or ivabradine (2.5, 5 or 10mg
twice daily) as the antianginal monotherapy plus short-
acting nitrates for 2 weeks. Prior to the randomization, the
eligible patients had an initial 2–7 days of antianginal med-
ication washing out; this included beta-blockers, calcium
channelblockersandlong-actingnitrates.Bicycleergometric
exercise tests were performed at the initial inclusion and end
of 2 weeks to assess time to 1mm horizontal ST depression
and limiting angina. After 2 weeks, the study was converted
to an open-label 2 or 3-months extension on ivabradine
10mg twice daily and then a 1-week randomized withdrawal
to ivabradine 10mg twice daily or placebo. At the end of 1-
week, another exercise test was performed.
Of the 360 eligible patients, 103 were excluded due to
protocol violation and the majority of them had negative
exercise tests at the time of randomization. In the remaining
257patients,thetimetohorizontalSTsegmentdepressionof
≥1mm, onset of angina and limiting angina is longer in all
ivabradine dose groups compared with the placebo, reaching
a statistical signiﬁcance (P = .04) at the dose of 10mg
twice daily. Resting and exercise heart rate in ivabradine
groups are signiﬁcantly lower than placebo (P<. 05).
In addition, the dose-dependent response was observed.
The frequency of angina attacks and use of short-acting
nitrates were also decreased in patients into the open-label
extension (P = .001). During the randomized withdrawal,
the frequency of angina increased in placebo group but
remained unchanged in ivabradine group.
The (International Trial of the Antianginal eﬀects if
Ivabradine Compared to Atenolol) INITIATE study involved
939 patients with stable angina randomized into ivabradine
5mg bid for 4 weeks followed by either 7.5 or 10mg bid
for 12 weeks or atenolol 50mg od for 4 weeks then 100mg
od for 12 weeks [26]. All patients underwent exercise stress
tests at the time of randomization and after 4 and 16
weeks of therapy. Total exercise duration at the end of the
4 weeks did not show signiﬁcant diﬀerence in ivabradine
and atenolol groups. The number of angina attacks was
decreased by two-thirds with both ivabradine and atenolol.
Thestudyconcludedthativabradineisaseﬀectiveasatenolol
in patients with stable angina.
The Antianginal property of ivabradine was also com-
pared with amlodipine (dihydropyridine calcium channel
blockers) in a 3 months double-blind trial [29]. 1195
patients with a ±3-month history of chronic stable angina
and documented CAD were randomized to three groups—
ivabradine 7.5mg bid (n = 400), ivabradine 10mg bid
(n = 391) and amlodipine 10mg od (n = 404). Patients
underwent bicycle exercise tolerance tests at randomisation
and every month for three months. The exercise tolerance,
time to limiting angina, time to angina onset and time to
1mm ST segment depression were consistently increased
in all groups without signiﬁcant diﬀerence. Of interest,
heart rates at rest and exercise were signiﬁcantly lower in
ivabradine groups compared with amlodipine.
Combination of ivabradine and dihydropyridine calcium
channel blockers was noted to be safe and well tolerated
in another trial which allowed concomitant medications
including long-acting nitrates or dihydropyridine calcium
channel blockers [30]. The resting heart rate was reduced
by 10bpm in patients receiving ivabradine 5mg bid and
12bpm in patients receiving 7.5mg bid. Of the 386 patients,
4 patients withdrew treatment due to visual side eﬀects and 3
patients had sinus bradycardia requiring discontinuation of
ivabradine. No ECG abnormality was detected in this study.
The number of angina attacks per week showed a signiﬁcant
reduction at the end of 1 year study in both ivabradine 5mg
bid and 7.5mg bid groups.
6. Conclusion
Available knowledge to date indicates that heart rate over
70bpm in patients with coronary artery disease and sys-
tolic heart failure of ejection fraction of less than 40%
is associated with adverse cardiac events. Currently, the
optimum therapeutic heart rate in these groups of patients
remains uncertain. The selective If inhibitor, ivabradine,
provides an alternative way of heart rate reduction in
addition to beta-blockers and calcium channel blockers.
This could become particularly useful in patients who are
intolerant of beta-blockers, for example, in the presence
of asthma or severe chronic obstructive airway disease.
At the treatment dose, it reduces heart rate to a similar
extent as atenolol and can be used together with beta-
blockers. Ivabradine is well tolerated in all the clinical
trials with minimal side eﬀects. The most common adverse
eﬀect is reversible visual symptoms. However, the absence
of sinus rhythm is currently the contraindication of its
use.
Further research is required to evaluate the mortality
beneﬁt of ivabradine in patients with known coronary
artery disease and systolic heart failure who are unable to
take beta-blockers. Clinical data suggests that ivabradine
can be used as an antianginal medication as monother-
apy or in combination with beta-blockers or calcium
channel blockers. Its Antianginal eﬀects are comparable
to atenolol and amlodipine in clinical trials. Selective If
inhibitor is likely to become another useful group of
medicine in cardiovascular disease management in the near
future.4 Cardiology Research and Practice
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